ExonHit Therapeutics SA And bioMerieux, Inc. Reach An Important Research Milestone In The Molecular Detection Of Breast Cancer From Blood Samples

March 29, 2006 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

ExonHit Therapeutics, a French drug and diagnostic discovery company, and bioMérieux, a major player in the field of in vitro diagnostics, announce today that they have reached an important research milestone in the diagnosis of breast cancer.

Twitter
LinkedIn
Facebook
Email
Print

Alliances Europe